Pain Clinical Trial
Official title:
A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia
Verified date | October 2023 |
Source | Kaohsiung Medical University Chung-Ho Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Fibromyalgia (FM) is a very common but mysterious pain disorder characterized by chronic widespread muscular pain. Fatigue, anxiety and depression are common comorbidities. The syndrome is commonly associated with several symptoms, including fatigue, sleeping disturbance, cognitive impairment, and comorbid pain syndrome, especially irritable bowel symptoms and temporomandibular disease. Anxiety and depression are common psychiatric co-morbidies. Daily stress is believed to trigger or aggravate pain conditions. These symptoms can markedly affect patients' quality of life, and even lead to disability. So far, the etiology and pathogenesis are largely unknown, and diagnostic biomarkers and curative treatment remain to be developed. Recent technological advances enable scientists to explore mechanisms by genetic, transcriptomic, proteomic, and metabolomic researches. However, no definitive result has been concluded for clinical practice so far. In this study, the investigators use tailored questionnaires to evaluate fibromyalgia and associated symptoms, including numeric rating scale for soreness, widespread soreness index, Fibromyalgia impact questionnaire, Hospital Anxiety and Depression Scale, and perceived stress scale. The investigators also use metabolomics and lipidomic approach to probe the potential pathophysiology of fibromyalgia. In our prior translation research (PMID: 32907805), the investigators found that excessive LPC16:0 resulting from lipid oxidization inflicts psychological stress-induced chronic non-inflammatory pain via activating ASIC3. In this content, our prior translational research identified a potential nociceptive ligand that causes fibromyalgia symptoms, which is likely to function as biomarkers for diagnosis or disease monitor. In the current clinical investigation, the investigators aim to reversely translate the novel findings in animal studies and validate the bio-significance of LPC16:0 for fibromyalgia with clinical approaches.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | July 31, 2027 |
Est. primary completion date | July 31, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Clinical diagnosis of fibromyalgia Exclusion Criteria: 1. Systemic rheumatological or immune disorders (e.g., systemic lupus erythematosus, inflammatory myositis), 2. Systemic use of corticosteroids, 3. Pregnancy, 4. Chronic diseases under poor control 5. Malignancies. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Kaohsiung Medical University Hospital | Kaohsiung |
Lead Sponsor | Collaborator |
---|---|
Kaohsiung Medical University Chung-Ho Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Questionnaire: Numeric rating scale (NRS) for pain and soreness | assessment of pain and soreness severity. Score: 0(no symptom) ~10 (worst symptom) | Changes from baseline NRS at 2 weeks are assessed | |
Primary | Questionnaire: Numeric rating scale (NRS) for pain and soreness | assessment of pain and soreness severity. Score: 0(no symptom) ~10 (worst symptom) | Changes from baseline NRS at 4 weeks are assessed | |
Primary | Questionnaire: widespread pain index and widespread soreness index | assessment of pain and soreness diffuseness. Score: 0(no symptom) ~19 (mostly diffused symptom) | Change from baseline widespread index at 2 weeks are assessed | |
Primary | Questionnaire: widespread pain index and widespread soreness index | assessment of pain and soreness diffuseness. Score: 0(no symptom) ~19 (mostly diffused symptom) | Change from baseline widespread index at 4 weeks are assessed | |
Primary | Questionnaire: Fibromyalgia impact questionnaire (FIQR) | assessment of fibromyalgia impacts and disease severity. Score: 0(no symptom) ~100 (worst symptom) | Change from baseline FIQR at 2 weeks are assessed | |
Primary | Questionnaire: Fibromyalgia impact questionnaire (FIQR) | assessment of fibromyalgia impacts and disease severity. Score: 0(no symptom) ~100 (worst symptom) | Change from baseline FIQR at 4 weeks are assessed | |
Primary | Questionnaire: Hospital Anxiety and Depression Scale (HADS) | assessment of psychological distress. Score: 0 (no symptom) ~42 (worst symptom) | Change from baseline HADS at 2 weeks are assessed | |
Primary | Questionnaire: Hospital Anxiety and Depression Scale (HADS) | assessment of psychological distress. Score: 0 (no symptom) ~42 (worst symptom) | Change from baseline HADS at 4 weeks are assessed | |
Primary | Questionnaire: The Pittsburgh Sleep Quality Index (PSQI) | assessment of sleep quality. Score: 0 (no symptom) ~21 (worst sleep quality) | Change from baseline PSQI at 2 weeks are assessed | |
Primary | Questionnaire: The Pittsburgh Sleep Quality Index (PSQI) | assessment of sleep quality. Score: 0 (no symptom) ~21 (worst sleep quality) | Change from baseline PSQI at 4 weeks are assessed | |
Primary | Questionnaire: Perceived stress scale (PSS) | assessment of perceived stress loading. Score: 0 (no stress) ~40 (highest stressed level) | Change from baseline PSS at 2 weeks are assessed | |
Primary | Questionnaire: Perceived stress scale (PSS) | assessment of perceived stress loading. Score: 0 (no stress) ~40 (highest stressed level) | Change from baseline PSS at 4 weeks are assessed | |
Primary | Metabolomics investigation | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. | Change from baseline metabolomics at 3 months are assessed | |
Primary | Lipidomics investigation | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. | Change from baseline metabolomics at 3 months are assessed | |
Primary | Metabolomics investigation | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. | Change from baseline metabolomics at 6 months are assessed | |
Primary | Lipidomics investigation | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. | Change from baseline metabolomics at 6 months are assessed | |
Primary | Metabolomics investigation | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. | Change from baseline metabolomics at 9 months are assessed | |
Primary | Lipidomics investigation | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. | Change from baseline metabolomics at 9 months are assessed | |
Primary | Metabolomics investigation | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. | Change from baseline metabolomics at 12 months are assessed | |
Primary | Lipidomics investigation | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. | Change from baseline metabolomics at 12 months are assessed |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|